An Unlikely Trio: Profound Anemia, Elevated Lactate, and Riociguat

Riociguat (Adempas) is a stimulator of soluble guanylate cyclase approved to treat adult pulmonary arterial hypertension (PAH), World Health Organization (WHO) group 1 pulmonary hypertension (PH), and inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH), WHO group 4 PH. Rio...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 14; no. 1; p. e20997
Main Authors Farmer, Mary Jo S, Farber, Harrison W
Format Journal Article
LanguageEnglish
Published United States Cureus 06.01.2022
Subjects
Cardiology
Pulmonology
chronic thromboembolic pulmonary hypertension
adempas
cteph
pah
pulmonary hypertension
lactate
pulmonary arterial hypertension
anemia
riociguat
Online AccessGet full text

Cover

More Information
Summary:Riociguat (Adempas) is a stimulator of soluble guanylate cyclase approved to treat adult pulmonary arterial hypertension (PAH), World Health Organization (WHO) group 1 pulmonary hypertension (PH), and inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH), WHO group 4 PH. Riociguat has been studied predominantly in WHO functional class II and III patients. In the pivotal Pulmonary Arterial Hypertension Soluble Guanylate Stimulator Trial 1 (PATENT-1) clinical trial, anemia was reported in 8% of patients; however, this anemia was typically very mild. We present a unique case of profound anemia and elevated lactate occurring in a patient taking riociguat for treatment of PAH.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.20997